DCOY · Decoy Therapeutics Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | $0 | $1.84M | $5.23M | $3.47M | $1.95M | $1.27M | $1.01M | $0 | |
| $250.35K | — | — | — | — | — | — | — | $430.75K | $506.53K | $662.75K | $0 | |
| $1.93M | — | — | — | — | — | — | — | $1.52M | $767.97K | $347.92K | $0 | |
| — | — | — | — | — | — | — | — | 77.93% | 60.26% | 34.42% | — | |
| $2.23M | $368.17K | $770.03K | $7.17M | $15.84M | $8.55M | $6.91M | $4.02M | $1.29M | $16.99M | $20.38M | $12.75M | |
| $4.1M | $3.73M | $4.96M | $5.72M | $7.14M | $6.1M | $6.11M | $7.71M | $2.35M | $18.5M | $19.86M | $16.46M | |
| $24.5K | $7151 | $4424 | $10.05K | $6677 | $19.18K | $18.06K | $127.41K | $16.95K | — | — | — | |
| — | — | — | — | — | — | — | — | $1.37M | — | — | — | |
| $14.84M | $12.61M | $5.73M | $12.89M | $31.84M | $14.65M | $13.02M | $11.73M | $3.64M | $36M | $40.9M | $29.21M | |
| -$14.84M | -$12.61M | -$5.73M | -$12.89M | -$31.84M | -$12.81M | -$7.79M | -$8.27M | -$1.68M | -$34.73M | -$39.89M | -$29.21M | |
| — | — | — | — | — | -696.27% | -148.78% | -238.53% | -86.33% | -2724.65% | -3946.54% | — | |
| -$14.82M | -$12.61M | -$5.73M | -$12.88M | -$31.83M | -$12.79M | -$7.77M | -$8.14M | -$1.67M | — | — | — | |
| $67.18K | — | — | — | — | — | — | — | $152.01K | $291.96K | $393.11K | $72.03K | |
| -$39.89M | — | — | — | — | — | — | — | — | — | — | -$29.21M | |
| — | $0 | — | — | — | — | — | $0 | — | — | — | — | |
| -$14.45M | -$12.52M | -$5.58M | -$12.54M | -$31.61M | -$12.77M | -$7.35M | -$6.94M | -$1.67M | -$34.43M | -$39.49M | -$29.14M | |
| — | — | — | — | — | -693.84% | -140.49% | -200.18% | -85.56% | -2701.74% | -3907.65% | — | |
| — | — | -$5.58M | -$12.54M | -$31.61M | -$12.77M | -$7.75M | -$6.94M | -$21.92M | -$34.43M | -$39.49M | -$29.14M | |
| -$8.26M | — | — | — | — | — | — | — | -$21.92M | -$34.43M | -$39.47M | -$29.17M | |
| USD/shares | $183.54 | -$129.10 | -$69.54 | -$5,533.20 | -$21,427.20 | -$11,116.80 | -$18,000.00 | — | — | — | — | — |
| USD/shares | $183.54 | -$129.10 | -$69.54 | -$5,533.20 | -$21,427.20 | -$11,116.80 | -$18,000.00 | — | — | — | — | — |
| shares | — | 96.97K | 80.18K | 2267.1 | 1475.3549 | 1149.0542 | 432.7392 | 90.7955 | 42.7608 | 479.4618 | 450.944 | 389.8032 |
| shares | — | 96.97K | 80.18K | 2267.1 | 1475.3549 | 1149.0542 | 432.7392 | 90.7955 | 42.7608 | 479.4618 | 450.944 | 389.8032 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2020: $133.59K in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2025-12-31 | USD 0 | 10-K filed 2026-03-31 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 99 similar-size Biotechnology companies (of 532 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$12,613,952 | -$5,734,316 | — |
| Reportable Segment | — | — | -$12,894,944 |